Phase I study dose escalation study for olaparib. 3 BRCA2-related chemotherapy refractory breast cancer patients were evaluable for the treatment efficacy; 1 OR and 1 SD were observed. No responses in BRCA-mutation-negative cases included in the study. Here, BRCA2 is linked to breast cancer.